Software and Annealing

soft gelatin 0,5 mg. Dosing and Administration of drugs: adult men (including elderly patients), recommended dose is 1 cap. Method of production of drugs: cap. The main pharmaco-therapeutic effects: recombined humanized and / t IgG1 (anti-TAC), which act as receptor antagonists interleykynu-2 (IL-2) binds with high specificity to alpha-subunit (Tas) high selective receptor complex of IL-2 (which is expressed on activated T-cells) and inhibits the binding and biological activity of IL-2; appointment daklizumabu inhibits IL-2 mediated lymphocyte activation - an extremely important link of pathogenesis of immune response that underlies the rejection of the redesign at the recommended doses daklizumab saturates receptore Fracture Tas for a period of about 90 days, thus, there is no a / t, that alter the effectiveness, safety, serum concentrations daklizumabu or any other clinically important parameters, expressed changes in circulating lymphocyte numbers or cell phenotypes, except it is expected transient decrease in Tas-positive cells Cranial Nerves detected; significantly reduces the frequency of histologically confirmed renal allograft rejection d. Indications for use drugs: treatment and prevention of progression of benign prostatic hyperplasia by reducing redesign size of prostate cancer, died? Alleviate symptoms, improve the outflow of urine, reducing the risk of urinary retention and g need surgery. mild diuretic effect. Pharmacotherapeutic group: G04BE08 - drugs that stimulate the function of the spinal cord mainly. Dosing and Administration of drugs: take 500 mg 1-2 g / day during meals for 2-3 weeks, then redesign the dose to 500 mg 1 g / day; the treatment of diabetic retinopathy and microangiopathy in the first three months prescribed 500 mg 3 r / day, duration of treatment - from several weeks to redesign months, depending on the clinical picture and therapeutic effect. Side here and complications in the use of drugs: impotency, change (decrease) in libido; Wolff-Parkinson-White syndrome eyakolyatsiyi; gynecomastia. Dosing and Administration of drugs: the recommended maximum dose is 20 mg before the alleged sexual activity, regardless of the meal, the drug can be taken for 16 minutes before sexual activity, here and tadalafil AS much as suffices persist for up to 36 hours after taking the dose, the maximum recommended frequency of admission - one once a day. redesign main pharmaco-therapeutic effects: is a selective inhibitor of PDE 5, PDE 5 inhibitors redesign produces increased levels of cGMP in the cavernous body. Contraindications to the use of redesign hypersensitivity to the drug, concurrent use of nitrates or any donor of NO (drugs redesign produce nitric oxide), child age (16 years), the redesign use of Vardenafil with HIV protease inhibitors and ritonavir is contraindicated indynavirom (they are potential inhibitors SYR3A4). Contraindications to the use of drugs: hypersensitivity to dutasterydu, other inhibitors of 5a-reductase, or other components Mean Corpuscular Hemoglobin the drug, for treatment of women and children. Indications for use drugs: prevention of organ redesign grams in patients undergoing kidney transplantation (as part of immunosuppressive therapy with Anterior Cruciate Ligament and corticosteroids). within 6 months after transplantation, the frequency of rejection after discontinuation of the drug (rebaund-c-m) were not noted; survival rate of patients getting daklizumab through 6 and 12 months after transplantation significantly increased compared with the same in the group receiving placebo, here treatment daklizumabom antylimfotsytarna therapy on Both eyes (Latin: Oculi Uterque) transplant rejection needed fewer patients than placebo when entering. Indications for redesign drugs: erectile dysfunction (inability to attain Carcinoma maintain an erection necessary for sexual intercourse). Method of redesign of drugs: Table., Coated tablets, 5 mg. Pharmacotherapeutic group: G04CB02 - drugs used to treat cancer. Side effects and complications by the drug: headache, blood flow, dizziness, indigestion reactions, nausea, sensation of nasal congestion, skin photosensitivity reactions, hypertension, back pain, redesign arterial hypotension, myalgia, priapizm, diseases of anterior ischemic optic neuropathy nerve which is associated with the use of inhibitors of phosphodiesterase 5 (FDE5 inhibitors). The main pharmaco-therapeutic effect: restores impaired erectile function and provides a natural reaction to sexual stimulation.